Kerendia has a different mode of action to the other emerging category of drugs for CKD associated with diabetes ... the results of a second phase 3 trial – FIGARO-DKD – that concentrated ...

and Eli Lilly/Boehringer Ingelheim's Jardiance (empagliflozin), two SGLT2 inhibitors which showed stronger effects on CKD in their phase 3 trials. Bayer's position is that Kerendia is not so much ...

With Novo Nordisk’s name already synonymous with treatments for diabetes and obesity, the Danish drugmaker has been making a ...

Akebia announced the collaborative trial initiation in September 2024 ... in March 2024 for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis ...

Akebia announced the collaborative trial initiation in September 2024. "We look forward to begin treating CKD anemia patients on dialysis with Vafseo ahead of its anticipated market launch in ...

Akebia announced the collaborative trial initiation in September 2024. "We look forward to begin treating CKD anemia patients on dialysis with Vafseo ahead of its anticipated market launch in January ...

Finerenone was first launched by Bayer under the brand name Kerendia ... CKD progression (level of recommendation A),” the company said in a statement. Based on the results of the clinical trial ...